# **Together we can beat cancer** Annual Report 2024-25 ## **Table of contents** |About Us ...............................................................................................................|3| |---|---| |Stem Cells ............................................................................................................|4| |Charitable Activities.............................................................................................|5| |Chairman’s Report ...............................................................................................|6| |Operation Director’s Report .................................................................................|7| |MCB Service..........................................................................................................|9| |Overview ...............................................................................................................|9| |Donate Clothes to Sammy ..................................................................................|11| |Research Priorities...............................................................................................|12| |Fundraising and Volunteers.................................................................................|13| |Thanks...................................................................................................................|14| |Trustees and Staff ...............................................................................................|14| |Accounts ..............................................................................................................|15| https://leukaemiamyelomaresearchuk.org 2 ## **About Us** _Leukaemia & Myeloma Research UK Ltd aims to prevent deaths from blood cancer through more effective treatments in the future. We are willing to fight blood cancer regardless of how long it might take._ Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment. Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That’s around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that’s 13 every day! We are aiming to become the UK’s leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children’s future health by storing their cord blood stem cells at the time of birth. There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma. The blood is made up of three different types of cells: - [Red blood cells which carry] - the oxygen around the body •[White blood cells which fight] - and stop infections •[Platelets which help the] blood to clot •[Raising awareness of stem] cell therapies The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant. •[Provide information] about blood cancers and treatment options •[Protecting the vulnerable by] offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby’s umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they are a suitable match. Leukaemia and Myeloma Research UK Ltd want to eradicate blood cancer once and for all. One of the ways we are aiming to achieve this is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do This service is called Model Cell Biobank (MCB). this by: •[Actively supporting stem cell] research into blood cancers 3 Tel: 0800 3687309 ## **Stem Cells** _In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues._ Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside. For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain. ## **Where are stem cells found?** There are four known accessible sources of autologous adult stem cells in humans: •[Bone marrow which requires ] harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic. •[Blood, which requires ] extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor. •[Adipose tissue (lipid cells), ] which requires extraction by liposuction. •[Umbilical cord blood - these ] stem cells can be collected from the umbilical cord blood just after birth. cell anaemia and aplastic anaemia. For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia’s, the treatments use allogeneic stem cell transplants (someone else’s stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease. ## **What can stem cells be used for today?** There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive. However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia’s and solid tumours) that are treated using autologous stem cells (using your own stem cells). There are other blood disorders that can be treated with stem cells that aren’t cancers, such as sickle https://leukaemiamyelomaresearchuk.org 4 ## **Charitable Activities** ## Providing Information Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. This has been achieved through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices. We produce a monthly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge. ## Medical Research Leukaemia & Myeloma Research UK Ltd allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity’s In conjunction with this, our fundraisers have been busy from running marathons, to organising golf days and completing sponsored bike rides. This has secured an amazing £88,766 of funding to support our services and help in the fight against cancer. ## Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC. ## Fundraising Activities Over the last year, the Charity expanded its textile recycling project so it now includes local schools and nurseries based in the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work. Model Cell Biobank Service This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease. The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells. 5 Tel: 0800 3687309 ## **Chairman’s Report** We started this busy year by participating in Acute Myeloid Leukaemia Awareness day, raising awareness about this rare form of cancer and the symptoms and treatments. We have also actively taken part in national awareness days including, Blood Cancer Awareness Month in September, World Cord Blood Day in November, and Myeloma Awareness Month in March. We have shared key facts and statistics, as well as stories from people directly impacted by blood cancer. Our biggest awareness campaign is Blood Cancer Awareness Month in September. This year we produced a video sharing information about blood cancer to educate the charity’s audience. We also shared 2 blood cancer patients stories highlighting the symptoms they first experienced, their diagnosis treatment and support they received. In July, our Research Review Committee met and awarded grants for 2 research projects, one investigating why some patients relapse after chemotherapy and the other looking at improving the efficiency of treatment for blood cancers. The Charity funded research in 2022 that has now led to a five-year Wellcome Postdoctoral Fellowship. The funding allows the researchers at the University of Oxford to continue the work and widen its investigations, with the potential to assist patients with other forms of cancer as well as AML. We are very proud to have been able to fund the initial work and to know that the continued work may have the potential to assist patients with other forms of cancer as well as AML. At the beginning of April 2024 we launched the Sammy Project which aims to raise funds and awareness of our work whilst giving a second life to preloved clothing donated by the community. We have been working with schools, nurseries, dance schools and Scouts across the North West. In 2025 the Charity turned 10. It has been fantastic to be able to review and reflect on the work that we have done as a Charity over the past 10 years. None of the work would be possible without the staff, volunteers and our incredible fundraisers. I would like to say a huge thank you to each and every one of them. Without them, we couldn’t continue to offer the services that we do and fight blood cancer. Sergejs Vinogradovs Chair, Leukaemia and Myeloma Research UK Ltd https://leukaemiamyelomaresearchuk.org 6 ## **Operation Director’s Report** Each year we receive fantastic support from our wonderful fundraisers. Around of 33% of the charity’s funding comes from individual donations and fundraising events, highlighting the reliance on the generosity of supporters. From marathons and golf matches to sponsored walks, there has been a variety of fantastic fundraising events to celebrate. A few highlights from the year are below. In May, two sisters ran the Hackney half marathon in memory of their grandad. They raised an amazing £5,000 towards our research programme. Hairdressing salon owner Rebecca Caraccio, from Whitstable, Kent, wanted to help others affected by the disease following the death of her 52-year-old brother, Michael Ingham. She raised just over £2,000 by running a half-marathon. At the beginning of the year Kevin Pluck, a keen golfer, took over the captaincy of the Kingsway Golf Centre in Cambridge, pledged to run a series of events throughout the year on behalf of LMRUK. Kevin lost both his parents to blood cancer, he explained: “I was 11 years old when my father was diagnosed and was given just months to live...when you’re a child your father is your idol, so it was pretty traumatic to be told he wouldn’t be around for long.” Throughout the year he raised over £2,100 which is fantastic. Another amazing runner is Rachel Handley who ran 10k following her mother’s myeloma diagnosis. Or Jacob Riley and his girlfriend Lydia Heaton, who raised more than £1,500 after completing a 10k sponsored run following a blood cancer diagnosis for Jacob’s sister. Wendy Forrest has taken part in her second Kiltwalk to raise money for our charity in memory of her husband, Alan. Wendy and five friends braved one of the hottest days of the year for the picturesque 20 mile walk from St Andrew’s to Slessor Gardens, Dundee. To date they have collected at least £2,225 for LMRUK. A couple embarked on a gruelling challenge to complete 100 miles in a month to raise money for LMRUK – after one of their parents was diagnosed with life-threatening Multiple Myeloma. Jonny Turner and Nichola Harrower from Wigan walked, ran and cycled to clock up the 100 miles all within a month during the summer and collected an impressive £1,310 in sponsorship money. “We read the fundraising stories on the website, ” Nichola said. “It saddened us to learn that LMRUK does not receive any government funding and so we decided a fundraising event would be an excellent place to start.” **----- Start of picture text -----**
Tel: 0800 3687309
**----- End of picture text -----**
7 Staff, governors and parents from a primary school in County Durham have raised over £1,000 for LMRUK with a 13-mile sponsored walk after their Deputy Head was diagnosed with leukaemia. We are incredibly grateful to each and every one of fundraisers and to those who make donations to the charity in memory of loved ones. Thank you so much for your wonderful support! In November, 4 friends successfully completed a 13-mile walk in memory of a colleague who passed away from a rare type of blood cancer securing over £1,800 towards our work. Our fundraisers of the year were announced in December, for the 2nd time the restaurant founders Elaine and Peter Kinsella won the award having raised over £23,000 in total for our Charity. Dr Joanna Tilley Operations Director, Leukaemia and Myeloma Research UK Ltd https://leukaemiamyelomaresearchuk.org 8 ## **MCB Service** ## **Overview** **The Model Cell Biobank (MCB)** service allows the storage of a child’s umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson’s disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs. When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future. The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks. We now offer a fully funded cord blood banking service to families who are on universal credit, with a history of cancer in the family. Alongside this, we also offer a part funded service to low income families. Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Smart Cells has a strong reputation for the high standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant. Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of. 9 Tel: 0800 3687309 ## **Advantages of Cord Blood Stem Cells** Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s. The stem cells in your baby’s cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders. •[A new born baby has been] exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient; •[Cord blood stem cells offer] the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem-cell collection, such as bone marrow; •[Cord blood stem cells can] be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored. Cord blood stem cells have many advantages including: •[They are easily available,] having already been harvested and stored; ## **Feedback from Clients** “I would really recommend storing stem cells from the umbilical cord blood to others. To use the service you have to have a history of cancer. It gives you a plan B should someone fall ill - and you never know what might happen in the future.” “Its like having a second plan in place if something should go wrong - an extra protection against ill-health. The procedure was very straight-forward and I would recommend it to others.” We didn’t know anything about the procedure but having a friend die from Leukaemia and another diagnosed when I was pregnant, made me more aware and I found out about what was involved.” “I really don’t know why we aren’t storing babies’ stem cells as a matter of course - it seems such a simple yet important thing to do.” “The team at LMRUK were so helpful and knowledgeable - they talked me through the whole process...they made the process straightforward from start to finish.” https://leukaemiamyelomaresearchuk.org 10 ## **Donate Clothes to Samm y** The Sammy Project was launched in April 2024 with the aim generating additional income to support the mission and causes of LMRUK charity, and to raise awareness of our work. The goal of the project is to raise extra funds by giving a second life to preloved clothing donated by the community via local schools, community centres, nurseries and other establishments. Our recycling programme secures valuable funds for the charities projects fighting blood cancer and raising awareness of our work. It also promotes re-use and recycling and encourages sustainable practices. According to The Times, British consumers spent £12.5 billion on clothing. The rising trend of “disposable” fashion has led to the dumping of 300,000 tonnes of textiles, exacerbating environmental pollution. Without significant changes in clothing production, usage, and disposal practices, projections suggest that global textile waste could reach 134 million tonnes by 2030. Due to the success of the project in the North West, we are planning to expand our services in West Yorkshire and Shropshire areas. We have had fantastic engagement from primary school and nurseries. The largest bag collection since the launch was from Farmworth Primary School with a total of 857kg, closely followed by Park View Primary school with 724kg, and St Bridget’s Primary school with 645kg. Thats 2.2 tonnes save from land fill! The project is managed entirely by the charity’s team without involving commercial companies, ensuring that 100% of the proceeds go directly to the charity. 11 Tel: 0800 3687309 ## **Research Priorities** Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants. In 2024-2025, to mark World Cancer Research day, LMRUK were pleased to have awarded £63,000 in grant funding to support two vital blood cancer projects. Assistant Professor Sophie Kellaway at the University of Nottingham will be undertaking specialist research into the regrowth of cells that cause the cancer, and whether they can be neutralised with the use of two drugs already available to treat conditions to help prevent the return of blood cancers. Professor Cristina Lo Celso and her PhD student Dr Germaine Chia of Imperial College London will be conducting a two year project that aims to improve the efficiency of treatment for blood cancers and reduce its toxicity. ## **Research Review Committee Members** **Professor Joseph R. Slupsky:** Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. **Dr Rhys Morgan:** Lecturer in Biomedical Sciences in Department of Biochemistry & Biomedicine, at the University of Sussex. **Dr John Jones:** Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital. **Dr Simon Richardson:** Senior Clinical Research Associate, University of Cambridge, Honorary Consultant Haematologist, Addenbrooke’s Hospital. **Dr Ceri Bygrave:** Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance. **Dr Paul Spencer Hole:** Senior Research Scientist. Engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company. **Dr Claire Seedhouse:** Associate Prof within Division of Cancer & Stem Cells & Principle Investigator & research group leader in Blood Cancer at the University of Nottingham. **Dr Sandeep Potluri:** Consultant Paediatric Haematologist/Stem Cell Transplantation and Clinician-Scientist, University of Birmingham. https://leukaemiamyelomaresearchuk.org 12 ## **Fundraisin and Volunteers g** _Founders of Lunya restaurant and deli, Elaine and Peter Kinsella have been named as our Fundraisers of the Year for their incredible work on behalf of our charity_ This is the second time that the duo has been named winners of the award, after jointly receiving the title in 2022. Elaine has been an innovator in finding new and effective ways to raise funds for our charity, enlisting the support of customers in the couple’s Liverpool restaurants to contribute to the cost of research into blood cancers. She and Peter, together with all their staff, raised £15,000 for LMRUK in 2022 by inviting customers of the Lunya and Lunyalita restaurants to add a pound to their bill every time they ate there. The initiative raised £7,500, generously matched by the couple themselves, making a total of £15,000. The success of the scheme prompted them to keep going, adding a further £7,657 to the pot, which was presented to our charity earlier this year. Elaine’s fundraising journey began after she was diagnosed with Myeloma following a routine blood test in 2021. She underwent initial treatment, then had a stem cell transplant in October of that year and came up with the fundraising idea while in recovery. Elaine said: “Peter and I are really happy to have been given this recognition for raising funds for such a good cause. I am currently receiving second line treatment for Myeloma and so have personal experience of how challenging a blood cancer diagnosis can be, but I am convinced that research into developing more treatments is the best way forward – this gives me hope for the future. “We could not have raised the money we have without the help of our wonderful customers at the two restaurants. It has been a real team effort with all our staff and very fitting in the year that our business became an Employee Owned Trust.” Dr Joanna Tilley, Operations Director at LMRUK, said that the award was in recognition of the money raised by Elaine – and the creative ways she had found to bring in funding for the charity. She added: “Elaine is a star. Fundraising is challenging in the current economic climate with household budgets tight. To get this kind of support from Elaine, her husband, staff, and their restaurant customers is a real boost for LMRUK and we are so grateful for their efforts.” This is just one of the many fantastic fundraisers that have kindly supported LMRUK over the past year - we simply could not run these services without them! Many thanks! 13 Tel: 0800 3687309 ## **Thanks to Funders** - [Dalgleish Trust] - [Rainford Trust] - [Ian Askew Charitable Trust] - [Santa Barbara Heights] - [Hilary Awdry Charitable Trust] - [Stanley Grundy Foundation] - [Carl Lewis Foundation] - [Mackintosh Foundation] - [Frank Litchfield General Charitable Trust] - [The Dixie Rose Findlay Charitable Foundation] - [Fort Foundationt] - [Sir Donald and Lady Edna Wilson] Charitable Trust - [Thomas Sivewright Catto] Charitable Settlement - [Postcode neighbourhood Trust] - [Stockwell Cliffe Charitable Trust] - [Albert Hunt Trust] - [LCVS Eli Lily and Elanco] - [Awards for All] - [N Smith Charitable Settlement] - [The Family Rich Charities Trust] ## **Staff and Trustees** ## **Trustees 2024-2025** - [Sergejs Vinogradovs][ (Chair)] - [Tatjana Vinogradova] - [Victoria Kieran] - [Julija Sidorika] ## **Staff Team** - Dr Joanna Tilley - Interim Operations Director - [Grace Trust] - [Aviva] - [John Raymond Tijou Charitable Trust] - [Worcester Bosch] - [Geoffrey and Pauline Martin trust] - [Warburtons] - [LCVS Resilience and Capacity One Knowsley] - [Hospital Saturday Fund] - [Stagecoach Giving] - [Arnold Clark Community Fund] - [M J C Stone Charitable Trust] - [Co-op Community Fund] - [Cecil and Hilda Lewis Charitable Trust] ## **Thanks to Individuals and supporters** - [Smart Cells International] - [KOR Communications] - [Research Review Committee] - [Best Freelance Design Ltd] - [Chester Handbooks] - [Fundraising Support Ltd] - [West Lancs & Merseyside Myeloma] Support Group - Kate Williams - PT Fundraiser - Karina Zaiceva - Department Manager - Aleashia Marland - Office Assistant - Richard Thompson - Call Centre https://leukaemiamyelomaresearchuk.org 14 Income and Expenditure Account for the year ended 31st March **2025** leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Company Limited by guarantee Registered number 09481278 ## **ACCOUNTS 31 MARCH 2025** ## **Leukaemia & Myeloma Research UK Ltd** ## **Report and accounts for the year ended 31 March 2025** ## **Contents** ||**Page**|| |---|---|---| |**Charity information**||1| |**Trustees' Annual Report**||1| |**Statement of directors' responsibilities**||5| |**Independent Examiner's Report**||7| |**_Funds Statements:-_**||| |Statement of Financial Activities||9| |Statement of Financial Activities - Prior Year statement||11| |Movements in funds||13| |Income and Expenditure account||14| |**Balance sheet**||15| |**Notes to the accounts**||17| ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2025** The Trustees present their Report and Accounts for the year ended 31 March 2025, which also comprises the Directors' Report required by the Companies Act 2006. ## **Reference and administrative details** ## _**The charity name.**_ The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd. The charity is also known by its operating name, LMR UK Ltd . ## _**The charity's areas operation and UK charitable registration.**_ The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622. The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland. The charity does not operate in any overseas jurisdictions. ## _**Legal structure of the charity**_ The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation. The governing document is dated 10 March 2015 There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law. By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals. ## **The principal operating address, telephone number, email and web addresses of the charity are:-** Unit 127, North Mersey Business Centre Woodward Road, Liverpool Merseyside, L33 7UY Telephone 08003687309 Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/ The registered office of the charity for Companies Act purposes is the same as the operating address shown above. 1 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2025** ## **The Trustees in office on the date the report was approved were:-** Sergejs Vinogradovs Tatjana Vinogradova Julija Sidorika Victoria Kieran ## **The following persons served as Trustees during the year ended 31 March 2025 :-** The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts. All the trustees are also members of the charity. ## **Objects and activities of the charity** ## _**The purposes of the charity as set out in its governing document.**_ The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are: 1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. 2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters. ## _**The main activities undertaken in relation to those purposes during the year.**_ Research grants are provided in order to promote the health of the public by research into the nature, cause, disnoses, preventon, treatment and cure of leukaemia and myeloma. ## _**The main activities undertaken during the year to further the charity's purpose for**_ ## _**the public benefit.**_ One research grant was provided this year totalling £39,959.58 Public awareness was a big focus this year with the charity undertaking the project of collecting clothes and selling these to raise funds. The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity. 2 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2025** ## **The main achievements and performance of the charity during the year.** As advised, the charity have been able to provide one large grants for research purposes. There was a large increase in awareness via the donation of clothes. More funds were in turn raised to support the charity. ## _**The difference the charity's performance during the year has made to the beneficiaries of the charity and wider society.**_ The charity was able to raise more funds this year which in turn raised awareness of the disease. This has benefited the wider society with more people being aware of the effects and the importance of research to support those living with the disease. ## **Structure, governance and management of the charity** ## _**The methods used to recruit and appoint new charity trustees.**_ Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees. ## _**The trustees' bankers and advisors**_ Accountants KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT ## **Financial review** ## _**The charity's financial position at the end of the year ended 31 March 2025**_ The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:- |Restricted Revenue Funds
**_Total Restricted Funds_**
**Total Funds**
Unrestricted Revenue Funds available for the
general purposes of the charity
**Net income**|**2025**
**£**
(146,864)
191,442
51,898
51,898
243,340|**2024**
**£**
37,883| |---|---|---| |||346,737
43,467| |||43,467| |||| |||390,204| 3 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2025** ## _**Financial review of the position at the reporting date, 31 March 2025 .**_ Overall surplus stands at £243,340 and will be distributed in the following way: £150,000 for Reserves, £25,000 for Research Grants, and £68,340 for charity development, including MCB, e- shop, and the Donate Clothes 4 Sammy project. The trustees consider the financial performance by the charity during the year to have been satisfactory. ## _**Policies on reserves.**_ The trustees collectively aim to maintain free reserves in unrestricted funds within a range equivalent to twelve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees to ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy will undergo an annual review, aligning with the scrutiny of the charity's annual accounts. In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the trustees have determined that a prudent Reserves amount must be set at £150,000. This decision is reflective of the charity's commitment to financial resilience and its responsiveness to the evolving economic landscape. ## _**Availability and adequacy of assets of each of the funds**_ The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund. ## **Details of The Independent Examiner** Olivia Higgins FCCA Member of Chartered Certified Accountants 255 Poulton Road Wallasey Wirral CH44 4BT 4 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2025** ## **Statement of the Directors' and Trustees' Responsibilities** The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), . In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :- - to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). - select suitable accounting policies and apply them consistently; - make judgements and estimates that are reasonable and prudent; - prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business; - state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year. The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements. 5 Leukaemla & Mydorna ReS9￿h UK Lld Company R8gistraUon Number- 09481278 Trugtees, Annual Report for tho year endod 31 March 2025 Melhod of prepar8tlon of accounts- Small company wovlslons The finan￿￿ slal&m8nls are sel out on pw 9 10 36. The financa￿ statarnants have ￿en prepar￿ Inp￿￿ltI￿j thg FRS 102 SORP Islatemgnl of R￿mmended Pract1￿ for Acwunting and ReportirKJ by Charfliesl 2019, appli¢able to all accounting Ixglnnlng on or aft￿ 1st January 20191.. (The SC%IPI. In a￿rdance the Fir￿nCl￿ FleDOrtina StarKlard 102. leff￿￿Ve 1s1 JanuaN 20161 These firwci8J stalemenis have prepared in accordance Mth prcmsions in Part 15 of the Companles Act 2CIJ6. apF4c814e to cowpanies YJWI to the small companl8s rgglm8. Trls reFM)rt was aFvovwJ bylhe L*lnth 4%DetyJ&f TATJANA VIN(￿RADOVA Dlrector aThY Trusteg ## **Leukaemia & Myeloma Research UK Ltd** ## **Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2025** I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 36 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 17. ## **Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report** As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view. The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination. Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:- a) examine the financial statements of the charity under Section 145 of the Act; b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act. ## **Basis of Independent Examiner's Statement and scope of work undertaken** Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies. I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP. The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below. 7 Leukaemia & Myeloma Research UK Ltd I planned and p8rtormed my Èxaminabon so as lo satisfy myself that the objealives ol IhB inllgpendenl 8xaminalvJ ar8 achi8ved and before linalisino the report l obtained writt8n asstsran¢ES from thE Tru51ees ol all maierial matters. Independent Examlnerfs Statement, Reportand Oplnion Att8nlon is drawn lo the accounliw policy slating thai, noiv*ihsiarbding the eXp5￿1t r8quir8ment in th8 8Xtani siaiulory rÈgDlabOnS, the Charities (Accounts and Reportsl Regulations 2008, lo prepare the financial siaiemenis in accordance with thè SORP 2005. in view ol rh& laci thai lae sO￿P 2005 ha5 been withdrawn, and in order 10 accord ltt curr8ni besi praciice. the Trustees have de18rmined to prepare the financial stalemeD15 In accordance wilh Ihe FRS 102 soRp Isiatemeni ol RpcotDfflend6d Practic8 lor Accounting and Reporting by Chariliesl 2019, applicabl& to all accouniing periDds b2gi￿rning on or after 181 January 20191, (The SORPI. I concurwlh Ihis approach. and any relerences in tny report lo the re9ulalions should b8 read $ubjErt lo thi5 comment. Subject lo the limitations upon ihe sto￿ of my work as detailed abov8, I have comrAeied my exatDinalion'. and can conlirFn Ihal'.- The accounts ol this ch2ritaNe company w ntst requwed to b& auditad und8r Part 16 of the Gowpanie5 Act 20LX%,. The gr05s incom8 ol the chariiable company in the year ended 31 March 2025 appeats lo exceed the sum sp8cified in Section 145131 ol Ihe Aci, namÈly £250000, and that l am qua1i118d 10 aci as Independent Examiner in accordance wlh thai s8ciion by virtu8 of my 8 qualified mernber ol Charter8d CÈrtilied A¢wuDlanls'. rhis Is a rsport in ￿5p￿¢t ol an examinat￿n carriad out undpr 145 01 the Act and in arxordanc8 Directions given by th8 Charity CotllTnission under section 14515llbl of the AGI which tnay be applicable". anrl Ihat no material Tnatters hav8 com8 lo my atEenuon in connection wlh the exaffiination giwng me caus8 10 believe thai in any materia1 resoecl.'_ accounting recard5 were not kept in respeci ol th8 charity 85 required by Section 386 01 th8 Companies Ad 2008 and Section 130 01 The Charities Act 2011.. the linancial statements do not attofd ￿th Ihose record5,' or thè linanGial ststemenls do nol comply ¥￿th the applicable requir6rn8nts conceming the form and ¢onieni of accoDntS Sel out in seGlion 396 of the Companies Aci 2006 other than any r8quir8m8ni Ihal the ar£ounts uivÈ a Yme and lair, view. which 15 nol a matter considtrred as part ol an indepgrfenl 8xaminahon." have noi been prepared in acwrdanGg wlh the methods and princIp￿S sei out in Ihe FRS 102 SORP Islalemeni ol R8commended Practice for Accouniing and Reporting by Charitie512019. applicable to 811 counting peiiods beginning on ur after 1st January 20191, IThe SOAPI. I have no t0￿CernS and have coffje across no Other matters in ¢onneGb'on the 8xaminaiion to %**ich attention shoukl be dra¥￿ in thi5 report in ord8r to enable a praper uT￿erstan(￿lfjg ol the linanaal staiements to be reached. Siyned:. kli Olivia Higgin ndependenl Examin8r Cttarter8d Cèrtified AG¢ounlan15 255 Poullon Aoad Wallasey Witr CH44 4BT This report was 5NJned on 12 2025 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025** _**Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2025, as required by the Companies Act 2006)**_ |**Income & Endowments from:**
Donations & Legacies
A1
Charitable activities
A2
Investments
A4
Other
A5
**Total income**
**A**
**Expenditure on:**
Raising funds
B1
Charitable activities
B2
**Total expenditure**
**B**
**Net income for the year**
**Total funds brought forward**
**Total funds carried forward**
**SORP**
**Ref**
**Net movement in funds**|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
164,964
279,394
3,742
50,000
**498,100**
16,473
636,922
**653,395**
**(155,295)**
**(155,295)**
346,737
**191,442**
|**Current year**
**Restricted**
**Funds**
**2025**
**£**
55,505
-
-
332
**55,837**
-
47,406
**47,406**
**8,431**
**8,431**
43,467
**51,898**|**Current year**
**Total Funds**
**2025**
**£**
**220,469**
**279,394**
**3,742**
**50,332**
**553,937**
**16,473**
**684,328**
**700,801**
**(146,864)**
**(146,864)**
**390,204**
**243,340**|**Prior Year**
**Total Funds**
**2024**
**£**
242,837
63,177
4,317
50,000| |---|---|---|---|---| |||||**360,331**| |||||14,389
308,059| |||||**322,448**| |||||| |||||**37,883**| |||||**37,883**
352,321| |||||**390,204**| The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet. A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses. All activities derive from continuing operations **The notes attached on pages 17 to 36 form an integral part of these accounts.** 9 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025** **Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP** **Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP** |Donations & Legacies
A1
Charitable activities
A2
Investments
A4
Other
A5
**Total income**
**A**
**Expenditure on:**
Raising funds
B1
Charitable activities
B2
**Total expenditure**
**B**
**Net income for the year**
**Total funds brought forward**
**Total funds carried forward**
**Net movement in funds**
**SORP**
**Ref**|**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
191,132
63,177
4,317
50,000
308,626
14,389
259,235
**273,624**
35,002
**35,002**
311,735
**346,737**

|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
51,705
-
-
-
-
51,705
-
48,824
**48,824**
2,881
**2,881**
40,586
**43,467**|**Prior Year**
**Total Funds**
**2024**
**£**
**242,837**
**63,177**
**4,317**
**50,000**
**360,331**
**14,389**
**308,059**
**322,448**
37,883
**37,883**
**352,321**| |---|---|---|---| ||||**390,204**| ## **All activities derive from continuing operations** A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.' ## **The notes attached on pages 17 to 36 form an integral part of these accounts.** 10 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025** ## **Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2025 towards fixed assets for Charity use:-** |**2025 towards fixed assets for Charity use:-**||| |---|---|---| |Funds generated in the year as detailed in the SOFA
Resources applied on functional fixed assets
**Net resources available to fund charitable activities**|**2025**
**£**
-
(57,700)
**(57,700)**|**2024**
**£**
-
(24,570)| |||**(24,570)**| The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals. **The notes attached on pages 17 to 36 form an integral part of these accounts.** 11 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025** ## **Movements in revenue and capital funds for the year ended 31 March 2025** ## **Revenue accumulated funds** |**Unrestricted**
**Funds**
**2025**
**£**
Accumulated funds brought forward
346,737
(155,295)
**191,442**
**Closing revenue funds**
**191,442**
**Summary of funds**
**Unrestricted**
**and**
**Designated funds**
**2025**
**£**
Revenue accumulated funds
191,442
**Total funds**
**191,442**
Recognised gains and losses before
transfers|**Restricted**
**Funds**
**2025**
**£**
43,467
8,431
**51,898**
**51,898**
**Restricted**
**Funds**
**2025**
**£**
51,898
**51,898**|**Total**
**Funds**
**2025**
**£**
390,204
(146,864)
**243,340**
**243,340**
**Total**
**Funds**
**2025**
**£**
**243,340**
**243,340**|**Last year**
**Total Funds**
**2024**
**£**
**352,321**
37,883| |---|---|---|---| ||||**390,204**| ||||**390,204**| ||||**Last Year**
**Total Funds**
**2024**
**£**
390,204| ||||**390,204**| **The notes attached on pages 17 to 36 form an integral part of these accounts.** 12 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025** ## **Leukaemia & Myeloma Research UK Ltd** ## **Income and Expenditure Account for the year ended 31 March 2025 as required by the Companies Act 2006** |**_Income_**
Income from operations
Interest receivable
Other operating income
**Gross income in the year before exceptional items**
**Gross income in the year including exceptional items**
**_Expenditure_**
Charitable expenditure, excluding depreciation and amortisation
Depreciation and amortisation
Fundraising costs
**Total expenditure in the year**
**Retained surplus for the financial year**
**Net income before tax in the financial year**
Investment income|**2025**
**£**
499,857
3,742
50,332
**553,937**
**553,937**
663,361
20,967
16,473
**700,801**
**(146,864)**
**(146,864)**|**2024**
**£**
306,014
4,317
50,000| |---|---|---| |||**360,331**| |||**360,331**| |||300,892
7,167
14,389| |||**322,448**| |||**37,883**| |||**37,883**| All activities derive from continuing operations In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities. 13 L8uka8mla & Myeloma Research UK Ltd- Balance Shoot as at 31 Mgrch 2025 2024 Flxed ossots Tar#JiV￿ assèts 19,227 Total lIx￿ a8se18 19.227 Curront a#ets B1 550 12.036 171.2n 27,319 12,326 335.511 D8btor5 Cash al trwl( and kn Total rurrBnt asse18 215M59 375,156 Cr•Jllors'. amunts Ia]1kngd￿Vllll onèy g C1 128,4791 14,1791 le7,￿0 370,977 Th8total n8t485at8 ol the 390204 Th•total net as￿* olth• we fundod by th8 ofthèdority. asfolo** R88trkt¢d lund¥ R8slrictsd R8¥emg Fwds 11 D2 51, 48,467 51.898 l￿￿¥trIctl￿ Fund Unrestrtted RevEnUg Fur 191,442 346.737 191.442 346.737 Total thartty lund6 390204 Th8'SOAP Aef [r￿l￿ted alMp•e is t￿ClaSSIca￿)n ol iients as setwt in thg forrn￿ ￿F1P dttumonts. As wlred by paraorw 4.60 ofth? SORP. fv t*wght fLKward aThl fornwd lurrfls havè boen agro&1 to SOFA.. Ihe dlfQ¢W5 ar8sats5f*d Ih81 th8wmrAny Isenbubjto from r8quwpm8Tht b own an awjltuntsr Sg¢tknn 477 of fv Q(Knpan￿S kl 21JX. The Thmb8r8 havè wtswlrad (¥)mpanyfO obtawlaTra￿* In •xfxdatr• 59LaK)Tr 476 of the ACL Th8 (*q¢tcJrs a(*nohledg8 their resp)￿￿1&￿.8S for YAth tha Compth85 kt2Th wllh veywl to wuntirwj rBGtydsa￿I the try8raihJn of at￿nts. The ¢h&rfty is sutwctto Ind8F*￿￿ Eyamlnakn LFthr clwrity aNI Ihe fwtofthe Inc*Férnbnl Examiner Is on P￿68. ThÈ finartrlal statemeNs h￿t￿l w8paTrd In ac{Xxdan￿t￿Ith1hE n Part 15 Oltho C￿mPan￿5 Ad 2006. aFpll¢able IDa)rrpsr￿ s&Jpct to srnaH rtsntgries wiTh. TATJANA vINC￿FIAL￿lVA T￿stee Arvov8d hy thèboartl of lrt*ts0s L The nofg¥attach8d on p8ge$ 17to 361ornhan part of lh￿SCoY￿ 14 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## **1 Accounting policies** ## _**Policies relating to the production of the accounts.**_ ## **Basis of preparation and accounting convention** The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice. ## **Going Concern** The charitable activities are entirely dependent on continuing grant aid and voluntary donations as well as trading revenues. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. Other than these matters, the Trustees are not aware of any material uncertainites about the charity's ability to continue as a going concern. ## _**Policies relating to categories of income and income recognition.**_ ## **Nature of income** Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers. ## **Categories of Income** Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income. **Income from exchange transactions** is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser. **Income from a non-exchange transaction** is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange. ## **Income recognition** Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably. Dividends are accrued when the shareholder’s right to receive payment is established. Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met. All income is accounted for gross, before deducting any related fees or costs. 15 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## **Income from legacies** Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met. Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable. Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy aredisclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant. If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities ## **Donated goods, facilities and services** **Donated fixed assets** are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets. **Donated goods that are not fixed assets** are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items. In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales. If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense. The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made. The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in _'legacies and donations_ '. Goods donated for resale are included in _'Income from other trading activities'_ The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner. **Donated services and facilities** (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity. All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value. 16 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## _**Policies relating to expenditure on goods and services provided to the charity.**_ ## **Recognition of liabilities and expenditure** A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.. Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates. ## **Allocating costs to activities** Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities. The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :- **Staffing** - on the basis of time spent in connection with any particular activity. **Premises related costs** - on the proportion of floor area occupied by a particular activity. **Non specific support costs** - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures ## _**Policies relating to assets, liabilities and provisions and other matters.**_ ## _**Tangible fixed assets**_ Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition. Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives. Plant and machinery 25 % straight line Motor vehicles 25 % straight line A regular annual review of the likelihood of asset impairment is undertaken. 17 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## **Accounting for capital grants and fixed asset funds.** Gifts of tangible fixed assets or grants of a capital nature, given for the purposes of acquiring specific assets to be fully utilised in the furtherance of the objects of the charity, are credited to fixed asset funds after the donated asset has been received or sums have been properly expended on the restricted purpose. Where the terms of the gift require the charity to hold the asset on an ongoing basis for a specific purpose, then the fixed asset fund so created is categorised as a restricted fixed asset fund, and the relevant restrictions are noted in the fixed asset note 6. Where the terms of the gift are met once the asset is acquired, so allowing the charity to use the asset on an unrestricted basis, including the right to receive the proceeds of any future sale of the asset on an unrestricted basis, then the fixed asset fund so created is categorised as a designated fixed asset fund. When assets are acquired for the furtherance of the charity's objects, utilising the charity's own unrestricted funds, a transfer is made from unrestricted funds to a designated fixed asset fund. Whether acquired with unrestricted or restricted funds, the asset acquired is initially shown in the balance sheet at the full cost of acquisition or subsequent revaluation. As the related assets are depreciated, in accordance with the depreciation policy,in order to reflect the dimunition in the asset,a transfer is made from the relevant fixed asset funds to either unrestricted or restricted revenue funds, as appropriate to the terms of the original gift, if any. The effect of this policy is that the aggregate of all fixed asset funds shall equate to the net book value of fixed assets. In the first year that this policy was adopted, a transfer to fixed asset funds was made equivalent to the net book value of the assets. Any residual liability to the donor arising from, for example, the asset's future sale, is disclosed as a contingent liability unless the event that would trigger repayment of the grant becomes probable in which case a liability for repayment is recognised. Insofar as this policy relates to Government grants and to the extent that it may be a departure from the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), such departure is justified on the basis that it is in order to comply with the SORP. ## **Stocks and work in progress** Stock is valued at the lower of cost and net realisable value. ## **Debtors** Debtors are measured at their recoverable amounts at the balance sheet date. ## **Creditors and provisions** Liabilities are measured at their settlement amount. A liability is recognised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide. ## **Financial instruments including cash and bank balances** Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements. ## **Fund Accounting** Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity. There are no endowment funds. 18 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## **2 Liability to taxation** The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. ## **3 Winding up or dissolution of the charity** If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity. ## **4 Defined contribution pension schemes** Any liabilites and assets associated with the scheme are shown under debtors and creditors. ## **5 Remuneration and payments to Trustees and persons connected with them** The trustees received payments in the amount of £1,082 as travel expenses related to providing services for clothing collection. ## **6 Tangible fixed assets** |**_Current Year_**
**Cost**
At 1 April 2024
Additions
**At 31 March 2025**
**Depreciation**
At 1 April 2024
Charge for the year
**At 31 March 2025**
**Net book value**
**At 31 March 2025**
**At 31 March 2024**|**Land and**
**Buildings**
£
-
-|**Plant &**
**Machinery**
£
4,674
39,255|**Motor**
**Vehicles**
£
23,995
18,445
**42,440**
5,999
10,610
**16,609**
**25,831**
**17,996**|**Total**
£
28,669
57,700| |---|---|---|---|---| ||**-**|**43,929**||**86,369**| ||-
-|3,443
10,357||9,442
20,967| ||**-**|**13,800**||**30,409**| ||**-**|**30,129**||**55,960**| |||||| ||**-**|**1,231**||**19,227**| 19 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** |**7**
**Stocks & Work in Progress**
Stocks before write downs
**8**
**Debtors**
Trade debtors
Prepayments and accrued income
Other debtors
**9**
**Creditors: amounts falling due within one year**
Bank loans and overdrafts
Accruals for grants payable
Trade creditors
Accruals
PAYE, NIC VAT and other taxes
Other creditors
**10 Particulars of how particular funds are represented by assets and liabilities**
**At 31 March 2025**
**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
Tangible Fixed Assets
55,960
-
Current Assets
163,961
Current Liabilities
(28,479)
-
**191,442**
**-**
**At 1 April 2024**
**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
Tangible Fixed Assets
19,227
-
Current Assets
331,689
-
Current Liabilities
(4,179)
-
**346,737**
**-**|**7**
**Stocks & Work in Progress**
Stocks before write downs
**8**
**Debtors**
Trade debtors
Prepayments and accrued income
Other debtors
**9**
**Creditors: amounts falling due within one year**
Bank loans and overdrafts
Accruals for grants payable
Trade creditors
Accruals
PAYE, NIC VAT and other taxes
Other creditors
**10 Particulars of how particular funds are represented by assets and liabilities**
**At 31 March 2025**
**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
Tangible Fixed Assets
55,960
-
Current Assets
163,961
Current Liabilities
(28,479)
-
**191,442**
**-**
**At 1 April 2024**
**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
Tangible Fixed Assets
19,227
-
Current Assets
331,689
-
Current Liabilities
(4,179)
-
**346,737**
**-**|**7**
**Stocks & Work in Progress**
Stocks before write downs
**8**
**Debtors**
Trade debtors
Prepayments and accrued income
Other debtors
**9**
**Creditors: amounts falling due within one year**
Bank loans and overdrafts
Accruals for grants payable
Trade creditors
Accruals
PAYE, NIC VAT and other taxes
Other creditors
**10 Particulars of how particular funds are represented by assets and liabilities**
**At 31 March 2025**
**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
Tangible Fixed Assets
55,960
-
Current Assets
163,961
Current Liabilities
(28,479)
-
**191,442**
**-**
**At 1 April 2024**
**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
Tangible Fixed Assets
19,227
-
Current Assets
331,689
-
Current Liabilities
(4,179)
-
**346,737**
**-**|**2025**
**£**
26,550
26,550
**2025**
**£**
840
-
11,196
**12,036**
**2025**
**£**
-
-
11,125
1,080
7,697
8,577
**28,479**
**Restricted**
**funds**
**£**
-
51,898
-
**51,898**
**Restricted**
**funds**
**£**
-
43,467
-
**43,467**|**2024**
**£**
27,319| |---|---|---|---|---| |||||27,319| |||||**2024**
**£**
6,000
294
6,032| |||||**12,326**| |||||**2024**
**£**
-
-
3,099
1,080
-
-| |||||**4,179**| |||||**Total**
**Funds**
**£**
**55,960**
**215,859**
**(28,479)**| ||**191,442**|**-**||**243,340**| ||**Unrestricted**
**funds**
**£**
19,227
331,689
(4,179)|**Designated**
**funds**
**£**
-
-
-||**Total**
**Funds**
**£**
**19,227**
**375,156**
**(4,179)**| ||**346,737**|**-**||**390,204**| 20 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## **11 Change in total funds over the year as shown in Note 10 , analysed by individual funds** |**Funds brought**
**forward from**
**2024**
**Movement in**
**funds in 2025**
**See Note 12**
**£**
**£**
**_Unrestricted and designated funds:-_**
Unrestricted Revenue Funds
346,737
(155,295)
**Total unrestricted and designated funds**
**346,737**
**(155,295)**
**_Restricted funds:-_**
Research
1,350
3,540
Model Cell Biobank
42,117
4,559
Sundry other funds
-
332
**Total restricted funds**
**43,467**
**8,431**
**Total charity funds**
**390,204**
**(146,864)**
**Analysis of movements in funds over the year as shown in Note 11**
**Income**
**Expenditure**
**2025**
**2025**
**£**
**£**
**_Unrestricted and designated funds:-_**
Unrestricted Revenue Funds
498,100
(653,395)
**_Restricted funds:-_**
Research
43,500
(39,960)
Model Cell Biobank
12,005
(7,446)
Sundry other funds
332
**553,937**
**(700,801)**|**Funds brought**
**forward from**
**2024**
**£**
346,737|**Movement in**
**funds in 2025**
**See Note 12**
**£**
(155,295)|**£**
**-**
**-**
-
-
-
**-**
**-**
**Other**
**Gains &**
**Losses**
**2025**
**£**
-
-
-
-
**-**
**Transfers**
**between**
**funds in 2025**|**Funds carried**
**forward to 2026**
**£**
**191,442**| |---|---|---|---|---| ||**346,737**|**(155,295)**||**191,442**| ||1,350
42,117
-|3,540
4,559
332||**4,890**
**46,676**
**332**| ||**43,467**|**8,431**||**51,898**| |||||| ||**390,204**|**(146,864)**||**243,340**| |||||**Movement**
**in funds**
**2025**
**£**
**(155,295)**
**3,540**
**4,559**
**332**| ||**553,937**|**(700,801)**||**(146,864)**| ## **12 Analysis of movements in funds over the year as shown in Note 11** 21 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2025** ## **13 The purposes for which the funds as detailed in note 11 are held by the charity are:-** ## _**Unrestricted and designated funds:-**_ These funds are held for the meeting the objectives of the charity, and to Unrestricted Revenue Funds provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use. _**Restricted funds:-**_ The purpose of these funds is described under the accounting Research policy. The purpose of these funds is described under the accounting Model Cell Biobank policy. ## **14 Ultimate controlling party** The charity is under the control of its legal members. For companies ltd by guarantee - Every member of the charity is obliged to contribute such amount as may be required to contribute to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member. 22 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** _**This analysis is classsified by conventional nominal descriptions and not by activity.**_ |**15**
**Donations, Grants and Legacies**
**Donations and gifts from individuals**
Refunds from HMRC on gift aided donations
Small donations individually less than £1000
CAF
**Total donations and gifts from**
**individuals**
Louise Bevan
GC C1
Facebook
Unity Lottery
Just Giving
Stripe Direct Donations
Charities Trust
Sheila Puzey
In Memory
Muchloved
Paypal Giving|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
2,302
6
10,973
4,784
-
37,866
1,646
5,665
1,217
7,970
1,450
1,703
1,557
1,208|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-
-
-
-
-
-
-
-
-
-
-
-
-
-|**Current year**
**Total Funds**
**2025**
**£**
**2,302**
**6**
**10,973**
**4,784**
**-**
**37,866**
**1,646**
**5,665**
**1,217**
**7,970**
**1,450**
**1,703**
**1,557**
**1,208**
**78,347**|**Prior Year**
**Total Funds**
**2024**
**£**
3,297
-
13,177
-
1,508
60,725
-
12,693
-
2,688
-
-
8,605
**3,367**| |---|---|---|---|---| ||**78,347**|**-**||**106,060**| **Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis** ||**Prior Year**|**Prior Year**||**Prior Year**| |---|---|---|---|---| ||**Unrestricted**|**Restricted**||**Total Funds**| ||**Funds**|**Funds**||| ||**2024**|**2024**||**2024**| ||**£**|**£**||**£**| |**Prior year**|**106,060**||**-**|**106,060**| 23 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**Legacies receivable**
**Legacies receivable - Prior Year analysis**
**Prior year**
Jackson Lees Group Ltd
David C Taylor
Holmes Mackillop
Nick Glynne/Martin Glynne
Small legacies individually less than £1000
**Total legacies receivable**
Oglethorpe & Broach
Catherine Dunne and Rachel O'Mallet
Holmes & Hills LLP|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
500
5,000
30,000
-
-
-
3,431
-|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-
-
-
-
-
-
-
-|**Current year**
**Total Funds**
**2025**
**£**
**500**
**5,000**
**30,000**
**-**
**-**
**-**
**3,431**
**-**
**38,931**
**Prior Year**
**Total Funds**
**2024**
**£**
**67,343**|**Prior Year**
**Total Funds**
**2024**
**£**
750
-
-
3,000
5,000
44,843
3,750
10,000| |---|---|---|---|---| ||**38,931**|**-**||**67,343**| ||**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
67,343|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-||| 24 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**Revenue grants from government and**
**public bodies**
**Total public sector revenue grants**
The Sunset Charitable Trust
L & R Gilley Charitable Trust
Small grants individually less than £1000
Orange Tree Trust
Hilary Awdry Trust
The National Lottery Community Fund
Medicash Trust
Rathbone Investment Management
Michael Watson Charitable Trust
John Mason Charitable Trust|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
1,680
-
-
-
-
8,880
-
-
-
-|**Current year**
**Restricted**
**Funds**
**2025**
**£**
65
-
-
-
-
-
-
-
-
-|**Current year**
**Total Funds**
**2025**
**£**
**1,745**
**-**
**-**
**-**
**-**
**8,880**
**-**
**-**
**-**
**-**
**10,625**|**Prior Year**
**Total Funds**
**2024**
**£**
2,890
2,500
2,000
3,000
3,500
-
3,000
2,500
2,500
5,000| |---|---|---|---|---| ||**10,560**|**65**||**26,890**| All the grants in the prior year were unrestricted. ## **Revenue grants from government and public bodies - Prior Year analysis** |**Prior Year**|**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
7,090|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
19,800|**Prior Year**
**Total Funds**
**2024**
**£**
**26,890**| |---|---|---|---| 25 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** ||**Current year**|**Current year**|**Current year**|**Current year**|**Current year**|**Prior Year**| |---|---|---|---|---|---|---| ||**Unrestricted**||**Restricted**||**Total Funds**|**Total Funds**| ||**Funds**||**Funds**|||| ||**2025**||**2025**||**2025**|**2024**| ||**£**||**£**||**£**|**£**| |**Revenue grants and donations from non**||||||| |**public bodies**||||||| |Small grants individually less than £1000||741||640|**1,381**|4,652| |Dalgleish Trust||-|2,000||**2,000**|-| |Fundraising Support Ltd||-|2,300||**2,300**|2,650| |Golders Green Foundation||||||| |||-||-|**-**|2,000| |The Rainford Trust||||||| ||1,000|||-|**1,000**|-| |Prowting Charitable Foundation||-||-|**-**|10,000| |Robert Luff Foundation||||||| |||-||-|**-**|10,000| |Albert Hunt Trust||||||| ||5,000||||**5,000**|| |Barratt Development||-||-|**-**|2,000| |Bognor Regis Golf Club|2,527|||-|**2,527**|2,767| |Cecil and Hilda Lewis Charitable||||||| |Trust|||2,000||**2,000**|| |Charity Job Giving|10,000||||**10,000**|| |CBRE ASD||||||| |||-||-|**-**|1,500| |Frank Litchfield General Charitable||||||| |Trust|||10,000||**10,000**|| |John Raymond TIJOU Charitable
Trust|||4,000||**4,000**|| |Kiwanis London||||||| |||-||-|**-**|2,000| |Lunya Limited|7,658||||**7,658**|| |Markeyl International||-||-|**-**|2,975| |Miss D.R Finlay Charitable Trust||-|3,000||**3,000**|| |MJ C Stone Charitable Trust||||||| ||2,200||||**2,200**|| |One Knowsley cancel alliance|2,000||||**2,000**|| |Postcode Neighbourho0d Trust|5,000||||**5,000**|| |Santa Barbara Heights Charitable
Trust|||1,000||**1,000**|| |Sir Donald Trust||||||| ||1,000||||**1,000**|| |The Carl Lewis Foundation||||||| ||||1,000||**1,000**|| |The Family Rich Church Trust|||5,000||**5,000**|| |The Fort Foundation||||||| |||-|2,000||**2,000**|| 26 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |The Gaynor Cemlyn-Jones Trust
The Geoofrey & Pauline Martin Trust
The Grace Trust
The N Smith Charitable Settlement
The Mackintosh Foundation
The Stanley Grundy Fondation Ltd
The Stockwell Clifee Charitable Trust
The Thomas Sivewright Catto
Charitable Settlement
The Hospital Saturday Fund
**Total private sector revenue grants**|-
-
-
-
-
-|1,000
10,000
2,000
2,000
1,000
1,500
1,000
3,000
1,000|**1,000**
**10,000**
**2,000**
**2,000**
**1,000**
**1,500**
**1,000**
**3,000**
**1,000**|**2,000**
**42,544**| |---|---|---|---|---| ||**37,126**|**55,440**|**92,566**|| All the grants in the prior year were unrestricted. **Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis** |**Prior Year**|**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
10,639|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
31,905|**Prior Year**
**Total Funds**
**2024**
**£**
**42,544**| |---|---|---|---| 27 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**Total Donations, Grants and Legacies**
**_Current year_**
**Unrestricted**
**Funds**
**2025**
**£**
**Total Donations, Grants and**
**Legacies**
**A1**
**164,964**
All the donations and gifts in the prior year were unrestricted.
**_Prior year_**
**Unrestricted**
**Funds**
**2024**
**£**
**Total Donations, Grants and**
**Legacies**
**A1**
**191,132**||||**Prior Year**
**Total Funds**
**2024**
**£**| |---|---|---|---|---| ||**Unrestricted**
**Funds**
**2025**
**£**|**Restricted**
**Funds**
**2025**
**£**|**Current Year**
**Total Funds**
**2025**
**£**
**220,469**
**Prior Year**
**Total Funds**
**2024**
**£**
**242,837**|| ||**164,964**|**55,505**||**242,837**| |||**Restricted**
**Funds**
**2024**
**£**||| ||**191,132**|**51,705**||| 28 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** ## **16 Income from charitable activities - Trading Activities** |**_Current year_**
**Primary purpose and ancillary trading**
**_Prior year_**
**Primary purpose and ancillary trading**
**Total Primary purpose and ancillary trading**
Sale of goods and services in accordance
with the charity's objects
**Total Primary purpose and ancillary**
**trading**
Sale of goods and services in accordance
with the charity's objects|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
279,394|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-|**Current year**
**Total Funds**
**2025**
**£**
**279,394**
**279,394**
**Prior Year**
**Total Funds**
**2024**
**£**
**63,177**
**63,177**|**Prior Year**
**Total funds**
**2024**
**£**
63,177| |---|---|---|---|---| ||**279,394**|**-**||**63,177**| ||**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
63,177|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-||| ||**63,177**|**-**||| 29 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** ## **17 Total Income from charitable activities** |**Current year**
**_Current year_**
**Unrestricted**
**Funds**
**2025**
**£**
Total income from charitable trading
279,394
**Total from charitable activities**
**A2**
**279,394**
**Income from charitable activities - Prior Year analysis**
**Prior Year**
**_Prior year_**
**Unrestricted**
**Funds**
**2024**
**£**
Total income from charitable trading
63,177
**63,177**
**18 Investment income**
**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
Bank Interest Receivable
3,742
**Total investment income**
**A4**
**3,742**
**Investment income - Prior Year analysis**
**Unrestricted**
**Funds**
**Prior Year**
**4,317**|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
279,394|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-|**Current year**
**Total Funds**
**2025**
**£**
**279,394**
**279,394**
**Prior Year**
**Total Funds**
**2024**
**£**
63,177
**63,177**
**Current year**
**Total Funds**
**2025**
**£**
**3,742**
**3,742**
**Total Funds**
**4,317**|**Prior Year**
**Total Funds**
**2024**
**£**
63,177| |---|---|---|---|---| ||**279,394**|**-**||**63,177**| |||**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-||**Prior Year**
**Total Funds**
**2024**
**£**
4,317| ||**63,177**|**-**||| ||**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
3,742|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-||| ||**3,742**|**-**||**4,317**| ||**Unrestricted**
**Funds**
**4,317**|**Restricted**
**Funds**
**-**||| 30 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**19 Other income and gains**
**_Current year_**
**Total other income**
**A5**
Royalties from the exploitation of
intellectual property rights
Sundry other income|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
50,000
-|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-
332|**Current year**
**Total Funds**
**2025**
**£**
**50,000**
**332**|**Prior Year**
**Total Funds**
**2024**
**£**
50,000
-| |---|---|---|---|---| ||**50,000**|**332**|**50,332**|**50,000**| ## **Other income and gains - Prior year analysis** |**Other income and gains - Prior year analysis**|||| |---|---|---|---| |**_Prior Year_**
**Total other income**
**A5**
Royalties from the exploitation of
intellectual property rights|**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
50,000|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-|**Prior Year**
**Total Funds**
**2024**
**£**
**50,000**| ||**50,000**|**-**|**50,000**| ## **20 Expenditure on charitable activities - Direct spending** |**_Current Year_**
**Total direct spending**
**B2a**
Costs of activities and events
Consultancy and professional support
Travel and Subsistence - Trustees Travel
Expenses
Travel and Subsistence - Charitable
Activities|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
592
16,161
47,968
-|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-
5,927
-
-|**Current year**
**Total Funds**
**2025**
**£**
**592**
**22,088**
**47,968**
**-**|**Prior Year**
**Total Funds**
**2024**
**£**
**470**
**20,878**
**38,586**
**1,082**| |---|---|---|---|---| ||**64,721**|**5,927**|**70,648**|**61,016**| All the expenditure in the prior year was unrestricted. 31 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**_Prior Year_**
**Total direct spending**
**B2a**
Consultancy and professional support
Travel and Subsistence - Charitable
Activities
Travel and Subsistence - Trustees Travel
Expenses
Costs of activities and events|**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
470
12,207
38,586
1,082|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-
8,671
-|**Prior Year**
**Total Funds**
**2024**
**£**
**470**
**20,878**
**38,586**
**1,082**| |---|---|---|---| ||**52,345**|**8,671**|**61,016**| **21 Expenditure on charitable activities - Charitable trading** |**_Current Year_**
**Total charitable trading costs**
**B2b**
**_Prior Year_**
**Total charitable trading costs**
**B2b**
Cost of Shipping, Freigh and Delivery
Cost of goods for primary purpose
trading - Including movement in stock
Cost of Shipping, Freigh and Delivery
Cost of goods for primary purpose
trading - Including movement in stock|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
**200,590**
**6,923**|**Current year**
**Restricted**
**Funds**
**2025**
**£**
**-**
**-**|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2025**
**2024**
**£**
**£**
**200,590**
**54,307**
**6,923**
**1,894**| |---|---|---|---| ||**207,513**|**-**|**207,513**
**56,201**| ||**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
54,307
1,894|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-
-|**Prior Year**
**Total Funds**
**2024**
**£**
**54,307**
**1,894**| ||**56,201**|**-**|**56,201**| ||||| **22 Expenditure on charitable activities- Grant funding of activities** |**_Current Year_**
**Total grantmaking costs**
**B2c**
Grants made to organisations|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
-|**Current year**
**Restricted**
**Funds**
**2025**
**£**
39,960|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2025**
**2024**
**£**
**£**
**39,960**
**57,500**| |---|---|---|---| ||**-**|**39,960**|**39,960**
**57,500**| 32 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**_Current Year_**
Imperial Colleage of Science,
Technology and Medicine
**_Prior Year_**
**Total grantmaking costs**
**B2c**
**23**
**_Current Year_**
**_Employee costs not included in direct costs_**
**_Premises Expenses_**
Rates and water charges
Salaries - Administrative staff
Defined contribution pension costs - Other
salaries
Subcontractors
Cleaning and waste management
**Breakdown of Grants made to organisations**
Grants made to organisations
Employers' NI - Administrative staff
**Support costs for charitable activities**
Storage
Service charges payable
Property insurance
Light heat and power
Premises repairs, renewals and
maintenance
Room Hire|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**|**Current year**
**Restricted**
**Funds**
**2025**
**£**
39,960|**Current year**
**Total Funds**
**2025**
**£**
39,960
**39,960**
**Prior Year**
**Total Funds**
**2024**
**£**
**57,500**
**57,500**
**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2025**
**2024**
**£**
**£**
**89,603**
**-**
**8,428**
**-**
**1,469**
**-**
**10,431**
**1,328**
**3,332**
**-**
**341**
**397**
**29,318**
**24,607**
**674**
**521**
**1,714**
**1,427**
**1,220**
**420**
**581**
**701**
**13,484**
**2,554**| |---|---|---|---| ||**-**|**39,960**|| ||**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
19,800|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
37,700|| ||**19,800**|**37,700**|| ||**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
89,603
8,428
1,469
10,431
3,332
341
29,318
674
1,714
1,220
581
13,484|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-
-
-
-
-
-
-
-
-
-
-
-|| 33 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**_Administrative overheads_**
3,319
-
**3,319**
1,648
-
**1,648**
1,284
-
**1,284**
11,015
-
**11,015**
4,314
-
**4,314**
4,163
-
**4,163**
6,951
-
**6,951**
84,343
1,519
**85,862**
381
-
**381**
1,848
-
**1,848**
20,714
-
**20,714**
**_Professional fees paid to advisors other than the auditor or examiner_**
1,830
-
**1,830**
19,626
-
**19,626**
21,625
-
**21,625**
**_Financial costs_**
65
-
**65**
**_Other costs_**
20,967
-
**20,967**
**Support costs before reallocation**
**364,688**
**1,519**
**366,207**
**Total support costs - Current Year**
**364,688**
**1,519**
**366,207**
The basis of allocation of costs between activities is described under accounting policies
Postage
Bank charges
Membership subscriptions
Hire of equipment
Accountancy fees other than examination
or audit fees
Management fees
Telephone, fax and internet
Advertising and marketing
Equipment expenses
Software licences and expenses
Stationery and printing
Liabilty and contents insurance
Motor Expenses
Sundry expenses
Depreciation & Amortisation in total for the
period
Other legal and professional|**_Administrative overheads_**
3,319
-
**3,319**
1,648
-
**1,648**
1,284
-
**1,284**
11,015
-
**11,015**
4,314
-
**4,314**
4,163
-
**4,163**
6,951
-
**6,951**
84,343
1,519
**85,862**
381
-
**381**
1,848
-
**1,848**
20,714
-
**20,714**
**_Professional fees paid to advisors other than the auditor or examiner_**
1,830
-
**1,830**
19,626
-
**19,626**
21,625
-
**21,625**
**_Financial costs_**
65
-
**65**
**_Other costs_**
20,967
-
**20,967**
**Support costs before reallocation**
**364,688**
**1,519**
**366,207**
**Total support costs - Current Year**
**364,688**
**1,519**
**366,207**
The basis of allocation of costs between activities is described under accounting policies
Postage
Bank charges
Membership subscriptions
Hire of equipment
Accountancy fees other than examination
or audit fees
Management fees
Telephone, fax and internet
Advertising and marketing
Equipment expenses
Software licences and expenses
Stationery and printing
Liabilty and contents insurance
Motor Expenses
Sundry expenses
Depreciation & Amortisation in total for the
period
Other legal and professional|**_Administrative overheads_**
3,319
-
**3,319**
1,648
-
**1,648**
1,284
-
**1,284**
11,015
-
**11,015**
4,314
-
**4,314**
4,163
-
**4,163**
6,951
-
**6,951**
84,343
1,519
**85,862**
381
-
**381**
1,848
-
**1,848**
20,714
-
**20,714**
**_Professional fees paid to advisors other than the auditor or examiner_**
1,830
-
**1,830**
19,626
-
**19,626**
21,625
-
**21,625**
**_Financial costs_**
65
-
**65**
**_Other costs_**
20,967
-
**20,967**
**Support costs before reallocation**
**364,688**
**1,519**
**366,207**
**Total support costs - Current Year**
**364,688**
**1,519**
**366,207**
The basis of allocation of costs between activities is described under accounting policies
Postage
Bank charges
Membership subscriptions
Hire of equipment
Accountancy fees other than examination
or audit fees
Management fees
Telephone, fax and internet
Advertising and marketing
Equipment expenses
Software licences and expenses
Stationery and printing
Liabilty and contents insurance
Motor Expenses
Sundry expenses
Depreciation & Amortisation in total for the
period
Other legal and professional|**3,319**
**1,648**
**1,284**
**11,015**
**4,314**
**4,163**
**6,951**
**85,862**
**381**
**1,848**
**20,714**
**1,830**
**19,626**
**21,625**
**65**
**20,967**|**1,921**
**1,053**
**1,608**
**8,568**
**1,414**
**1,339**
**3,968**
**30,326**
**-**
**2,045**
**3,867**
**240**
**32,638**
**5,121**
**112**
**7,167**| |---|---|---|---|---| ||**364,688**|**1,519**||**133,342**| ||**364,688**|**1,519**||**133,342**| |||||**-**
**-**
**-**| 34 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** |**Prior Year**
**Prior Year**
**Prior Year**
**_Prior Year_**
**Unrestricted**
**Funds**
**Restricted**
**Funds**
**Total Funds**
**2024**
**2024**
**2024**
**_Employee costs not included in direct costs_**
Subcontractors
1,328
-
**1,328**
**_Premises Expenses_**
Rates and water charges
397
-
**397**
Room Hire
24,607
-
**24,607**
Light heat and power
521
-
**521**
Cleaning and waste management
1,427
-
**1,427**
420
-
**420**
Property insurance
701
-
**701**
Storage
2,554
-
**2,554**
**_Administrative overheads_**
Telephone, fax and internet
1,921
-
**1,921**
Postage
1,053
-
**1,053**
Stationery and printing
1,608
-
**1,608**
Membership subscriptions
8,568
-
**8,568**
Equipment expenses
1,414
-
**1,414**
Hire of equipment
1,339
-
**1,339**
Software licences and expenses
3,968
-
**3,968**
Advertising and marketing
27,873
2,453
**30,326**
Sundry expenses
2,045
-
**2,045**
Motor Expenses
3,867
-
**3,867**
240
-
**240**
32,638
-
**32,638**
5,121
-
**5,121**
112
-
**112**
**_Other costs_**
7,167
-
**7,167**
**130,889**
**2,453**
**133,342**
**130,889**
**2,453**
**133,342**
The basis of allocation of costs between activities is described under accounting policies
Accountancy fees other than
examination or audit fees
**Total support costs - Prior Year**
Bank charges
Premises repairs, renewals and
maintenance
**_Support costs before reallocation_**
Management fees
**_Professional fees paid to advisors_**
Depreciation & Amortisation in total for
the period
Other legal and professional
**_Financial costs_**|**Prior Year**
**Unrestricted**
**Funds**
**2024**
1,328
397
24,607
521
1,427
420
701
2,554
1,921
1,053
1,608
8,568
1,414
1,339
3,968
27,873
2,045
3,867
240
32,638
5,121
112
7,167|**Prior Year**
**Restricted**
**Funds**
**2024**
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2,453
-
-
-
-
-
-
-|**Prior Year**
**Total Funds**
**2024**
**1,328**
**397**
**24,607**
**521**
**1,427**
**420**
**701**
**2,554**
**1,921**
**1,053**
**1,608**
**8,568**
**1,414**
**1,339**
**3,968**
**30,326**
**2,045**
**3,867**
**240**
**32,638**
**5,121**
**112**
**7,167**| |---|---|---|---| ||**130,889**|**2,453**|| ||**130,889**|**2,453**|| 35 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** ## **24 Total Charitable expenditure** |**_Current Year_**
Total direct spending
**B2a**
Total charitable trading costs
**B2b**
Total grantmaking costs
**B2c**
Total support costs
**B2d**
**Total charitable expenditure**
**B2**
**_Prior Year_**
Total direct spending
**B2a**
Total charitable trading costs
**B2b**
Total grantmaking costs
**B2c**
Total support costs
**B2d**
**Total charitable expenditure**
**B2**|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
64,721
207,513
-
364,688|**Current year**
**Restricted**
**Funds**
**2025**
**£**
5,927
-
39,960
1,519|**Current year**
**Total Funds**
**2025**
**£**
**70,648**
**207,513**
**39,960**
**366,207**
**684,328**
**Prior Year**
**Total Funds**
**2024**
**£**
**61,016**
**56,201**
**57,500**
**133,342**|**Prior Year**
**Total Funds**
**2024**
**£**
**61,016**
**56,201**
**57,500**
**133,342**| |---|---|---|---|---| ||**636,922**|**47,406**||**308,059**| ||**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
52,345
56,201
19,800
130,889|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
8,671
-
37,700
2,453||| ||**259,235**|**48,824**|**308,059**|| ## **25 Expenditure on raising funds and costs of investment management** |**_Current Year_**
Agent's costs for fundraising
Cost of fundraising activities
Fundraising trading costs
**Total fundraising costs**
**B1**
All the expenditure in the prior year was unrestricted.|**Current year**
**Unrestricted**
**Funds**
**2025**
**£**
13,245
2,507
721|**Current year**
**Restricted**
**Funds**
**2025**
**£**
-
-
-|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2025**
**2024**
**£**
**£**
**13,245**
**7,080**
**2,507**
**6,337**
**721**
**972**| |---|---|---|---| ||**16,473**|**-**|**16,473**
**14,389**| ||||| |**_Prior Year_**
Agent's costs for fundraising
Cost of fundraising activities
Fundraising trading costs
**Total fundraising costs**
**B1**|**Prior Year**
**Unrestricted**
**Funds**
**2024**
**£**
7,080
6,337
972|**Prior Year**
**Restricted**
**Funds**
**2024**
**£**
-
-
-|**Prior Year**
**Total Funds**
**2024**
**£**
**7,080**
**6,337**
**972**| |---|---|---|---| ||**14,389**|**-**|**14,389**| 36